Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCENIC: Secondary Neoadjuvant Chemotherapy in Recurrent Ovarian Cancer
NCT06292286Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by The University of Hong Kong. Primary endpoint: Complete resection rate at 12 months. Started Nov 2023; status: recruiting.
02
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06292286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292286.